Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | POLA1 | P09884 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7570951 | 0.92 | KDM1A (0.50) | KDM1ASIGMAR1POLA1CYP2C19CYP3A4 | |
| SCHEMBL8635505 | 0.92 | ALDH1A1 (0.41) | POLA1CYP2C9TSHRCYP2C19CYP3A4 | |
| SCHEMBL3905338 | 0.84 | OPRM1 (0.33) | KDM1ASIGMAR1KMT2A | |
| SCHEMBL9364462 | 0.84 | ADRA2A (0.43) | KDM1ASIGMAR1CYP3A4KMT2AKDM4E | |
| SCHEMBL3899441 | 0.83 | MEN1 (0.43) | KDM1ASIGMAR1KMT2A | |
| SCHEMBL3900065 | 0.83 | KDM1A (0.43) | KDM1ASIGMAR1ALDH1A1 | |
| SCHEMBL769008 | 0.83 | KDM1A (0.43) | KDM1ACYP3A4KDM4EJAK2ALDH1A1 | |
| SCHEMBL768934 | 0.83 | BACE1 (0.43) | KDM1A | |
| SCHEMBL2777365 | 0.80 | GAA (0.34) | CYP3A4ALDH1A1 | |
| SCHEMBL15897036 | 0.79 | BACE1 (0.37) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017123518-A1 | AMINOTRIAZOLE IMMUNOMODULATORS FOR TREATING AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017123518-A1 | AMINOTRIAZOLE IMMUNOMODULATORS FOR TREATING AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| US-20040198791-A1 | Fused imidazole derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1403256-A1 | FUSED IMIDAZOLE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198791-A1 | Fused imidazole derivative | H1-0, H1-5, H1-3 | KDM1A 2636/4885SIGMAR1 1826/4885POLA1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.